Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia

References

1. ↵
   1. Sudlow CL,
   2. Warlow CP

   (1997) Comparable studies of the incidence of stroke and its pathological types:Results from an international collaboration. International Stroke Incidence Collaboration. Stroke 28, 491–499.
2. ↵
   1. Benamer HT,
   2. Grosset D

   (2009) Stroke in Arab countries:a systematic literature review. J Neurol Sci 284, 18–23.
3. ↵
   1. Runchey S,
   2. McGee S

   (2010) Does this patient have a hemorrhagic stroke?Clinical findings distinguishing hemorrhagic stroke from ischemic stroke. JAMA 303, 2280–2286.
4. ↵
   1. Sacco RL,
   2. Adams R,
   3. Albers G,
   4. Alberts MJ,
   5. Benavente O,
   6. Furie K,
   7. et al.

   (2006) Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack:A statement for healthcare professionals from the American Heart Association/American stroke association council on stroke:co-sponsored by the council on cardiovascular radiology and intervention:the American academy of neurology affirms the value of this guideline. Circulation 113, 409–449.
5. ↵
   1. Ferguson AD,
   2. Dokainish H,
   3. Lakkis N

   (2008) Aspirin and clopidogrel response variability:review of the published literature. Tex Heart Inst J 35, 313–320.
6. ↵
   1. Giusti B,
   2. Gori A,
   3. Marcucci R

   (2010) Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmacogenomics Personalized Med 3, 33–50.
7. ↵
   1. Goldstein LB,
   2. Bushnell CD,
   3. Adams RJ,
   4. Appel LJ,
   5. Braun LT,
   6. Chaturvedi S,
   7. et al.

   (2011) Guidelines for the primary prevention of stroke:a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42, 517–584.
8. ↵
   1. Sukasem C,
   2. Tunthong R,
   3. Chamnanphon M,
   4. Santon S,
   5. Jantararoungtong T,
   6. Koomdee N,
   7. et al.

   (2013) CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. Pharm genomics Pers Med 6, 85–91.
9. ↵
   1. DeMorais SM,
   2. Wilkinson GR,
   3. Blaisdell J,
   4. Nakamura K,
   5. Meyer UA,
   6. Goldstein JA

   (1994) The major genetic detect responsible for the polymorphism of Smephenytoin metabolism in humans. J Biol Chem 269, 15419–15422.
10. ↵
    1. De Morais SM,
    2. Wilkinson CR,
    3. Blaisdell J,
    4. Meyer UA,
    5. Nakamura K,
    6. Goldstein JA

    (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46, 594–598.
11. ↵
    1. Sibbing D,
    2. Braun S,
    3. Morath T,
    4. Mehilli J,
    5. Vogt W,
    6. Schömig A,
    7. et al.

    (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53, 849–856.
12. ↵
    1. Gerotziafas GT,
    2. Zarifis J,
    3. Bandi A,
    4. Mossialos L,
    5. Galea V,
    6. Tsinopoulos G,
    7. et al.

    (2012) Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry. Clin Appl Thromb Hemost 18, 356–363.
13. ↵
    1. Gu S,
    2. Sun Y,
    3. Han R,
    4. Wang L,
    5. Wang D,
    6. Wang J,
    7. et al.

    (2014) Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese. BMC Med Genet 15, 83.
14. ↵
    1. Desta Z,
    2. Zhao X,
    3. Shin JG,
    4. Flockhart DA

    (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41, 913–958.
15. ↵
    1. Xie HG,
    2. Kim RB,
    3. Wood AJ,
    4. Stein CM

    (2001) Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41, 815–850.
16. ↵
    1. Wedlund PJ

    (2000) The CYP2C19 enzyme polymorphism. Pharmacology 61, 174–183.
17. ↵
    1. Saeed L,
    2. Mayet A

    (2013) Genotype-phenotype analysis of CYP2C19 in healthy Saudi individuals and its potential clinical implication in drug therapy. Int J Med Sci 10, 1497–1502.
18. ↵
    1. Gurbel PA,
    2. Bliden KP,
    3. Hayes KM,
    4. Yoho JA,
    5. Herzog WR,
    6. Tantry US

    (2005) The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45, 1392–1396.
19. ↵
    1. Angiolillo DJ,
    2. Fernandez-Ortiz A,
    3. Bernardo E,
    4. Alfonso F,
    5. Macaya C,
    6. Bass TA,
    7. et al.

    (2007) Variability in individual responsiveness to clopidogrel:clinical implications, management, and future perspectives. J Am Coll Cardiol 49, 1505–1516.
20. ↵
    1. Kreutz RP,
    2. Nystrom P,
    3. Kreutz Y,
    4. Miao J,
    5. Desta Z,
    6. Breall JA,
    7. et al.

    (2012) Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. Clin Pharmacol 4, 13–20.
21. ↵
    1. Sibbing D,
    2. Koch W,
    3. Massberg S,
    4. Byrne RA,
    5. Mehilli J,
    6. Schulz S,
    7. et al.

    (2011) No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 32, 1605–1613.
22. ↵
    1. Tresukosol D,
    2. Suktitipat B,
    3. Hunnangkul S,
    4. Kamkaew R,
    5. Poldee S,
    6. Tassaneetrithep B,
    7. et al.

    (2014) Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. PLoS One 9, e110188.
23. ↵
    1. Yang j,
    2. Zhao HD,
    3. Tan J,
    4. Ding YL,
    5. Gu ZQ,
    6. Zuo JJ

    (2013) CYP2C19 apolymorphisms and antiplatelet effects of cloperigdol in Chinese stroke patients. Pharmazie 68, 183–186.
24. ↵
    1. Hulot JS,
    2. Bura A,
    3. Villard E,
    4. Azizi M,
    5. Remones V,
    6. Goyenvalle C,
    7. et al.

    (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108, 2244–2247.
25. ↵
    1. Shuldiner AR,
    2. O’Connell JR,
    3. Bliden KP,
    4. Gandhi A,
    5. Ryan K,
    6. Horenstein RB,
    7. et al.

    (2009) Association of cytochrome P450 2C19 agenotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849–857.
26. ↵
    1. Mega JL,
    2. Close SL,
    3. Wiviott SD,
    4. Shen L,
    5. Hockett RD,
    6. Brandt JT,
    7. et al.

    (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360, 354–362.